Bid guide
How to bid on VA molecular residual disease testing
What the VA plans to buy
The Department of Veterans Affairs, Network Contracting Office 17, intends to award Natera a sole-source, firm-fixed-price IDIQ contract for molecular laboratory testing at VA facilities in Texas. The tests are used to evaluate and monitor transplant patients and cancer residual disease.
The notice estimates 35 Signatera tests and 25 Prospera tests across five ordering periods. This is a special notice, not a request for quotes, so it is an opportunity to show that an equivalent test is available—not to submit a standard price bid.
Dates and what the deadline means
The notice was published October 22, 2026. Capability statements are due November 2, 2026, at 10:00 a.m. CST.
The VA says it will review responses and retains discretion over whether to compete the requirement. The notice does not give a contract award date or exact dates for the five ordering periods.
Who this opportunity suits
This notice is relevant to clinical laboratories or other providers able to perform molecular genetic reference testing for transplant assessment and cancer residual disease monitoring.
A respondent must clearly demonstrate that an equivalent proprietary test exists and can be provided. The notice states that Natera’s named tests are proprietary and that no other vendor has the methods, assays, or intellectual property to perform those specific tests.
How to respond
Submit a capability statement by email to Susan Flores, Contract Specialist, NCO 17, at [email protected]. The deadline is November 2, 2026, at 10:00 a.m. CST.
To view the opportunity through the portal, click “View original source.” If the first click opens the portal homepage, click it again to go to the bid. A free account may be needed to view documents, though many bids do not require one.
Prepare a focused capability statement
State clearly which equivalent test you can provide and explain how it addresses the testing described in the notice: Prospera transplant assessment or Signatera residual disease testing. Include concrete evidence of your laboratory’s capability and the relevant testing methods, rather than relying on general claims.
Check that the response is complete, clearly identifies your organization, and reaches the named contact before the deadline. The VA says it is not responsible for costs incurred in responding.
See the live bid — deadline, agency details, and how to respond
Dates and requirements can change via addenda; always verify on the bid page and at the original source before responding.
View this bid on BiddingSimpleThis guide was prepared by BiddingSimple from the solicitation’s public posting. It is not official guidance from Veterans Affairs, Department of; the original posting controls.